Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618758 | 0.90 | WNT3A (0.35) | RAF1 | |
| SCHEMBL17624555 | 0.90 | KDM1A (0.35) | CA9RAF1 | |
| SCHEMBL19689755 | 0.83 | KIF18A (0.34) | RAF1 | |
| SCHEMBL19689757 | 0.83 | KIF18A (0.34) | RAF1 | |
| SCHEMBL16238670 | 0.82 | GRM5 (0.34) | EGFRRAF1 | |
| SCHEMBL19736200 | 0.82 | CNR2 (0.38) | — | |
| SCHEMBL17618465 | 0.82 | FAAH (0.38) | PIK3CANEK2MTOR | |
| SCHEMBL17618452 | 0.82 | MAPK14 (0.35) | PIK3CANEK2MTOR | |
| SCHEMBL19689733 | 0.81 | RAF1 (0.33) | RAF1 | |
| SCHEMBL19689734 | 0.81 | RAF1 (0.33) | RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA9 4248/4885PIK3CA 3691/4885EGFR 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.